title: Genome detection in liver and peripheral blood mononuclear cells: predictor factors of sustained response in patients with chronic hepatitis C.
abstract: BACKGROUND
  In chronic hepatitis C, relapses of liver disease occur in as many as 50% of patients responding to interferon (IFN) therapy. Although the presence of serum hepatitis C virus (HCV) RNA at the end of therapy predicts a relapse, its absence is not a reliable indicator of cure. In this study we have determined whether responders to IFN (normalization of liver chemistry and clearance of serum HCV-RNA) harbour HCV-RNA in the liver and peripheral blood mononuclear cells (PBMCs), and whether finding the genome at these sites has prognostic significance.
  
  
  METHODS
  After the conclusion of therapy, we tested for HCV-RNA in the liver of all the patients (anti-HCV-positive): 16 complete responders with normalization of liver chemistry and clearance of serum HCV-RNA and five non-responders. In 13 of the 16 complete responders we also tested for HCV-RNA in PBMCs. Patients were followed up for 9 months.
  
  
  RESULTS
  Liver HCV-RNA was detected in each of the five non-responders and in four of the 16 complete responders (25%). The viral genome was detected in the PBMCs of six complete responders (46%). During follow-up a relapse of hepatitis C occurred in the 10 complete responders with liver or PBMC HCV-RNA but in only one (16%) of the six complete responders without HCV-RNA in liver or PBMCs.
  
  
  CONCLUSIONS
  Reliable information on the prognosis of chronic hepatitis C responders can only be obtained by testing for HCV-RNA in serum, liver and PBMCs at the end of therapy. Patients with HCV-RNA at any of these sites stand a high risk of disease relapse. The risk is low but not abolished in patients without detectable HCV-RNA.
authors.affiliation: Department of Gastroenterology, La Fe Hospital, Valencia, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Berenguer
authors.forename: V
authors.initials: V
authors.lastname: Olaso
authors.forename: J
authors.initials: J
authors.lastname: Córdoba
authors.forename: M
authors.initials: M
authors.lastname: Gobernado
authors.forename: D
authors.initials: D
authors.lastname: Carrasco
authors.forename: J
authors.initials: J
authors.lastname: Berenguer
mesh_terms: D000368:Aged; D001483:Base Sequence; D002908:Chronic Disease; D017931:DNA Primers; D005260:Female; D005500:Follow-Up Studies; D016679:Genome, Viral; D016174:Hepacivirus / Q000235:genetics / Q000302:isolation & purification*; D006526:Hepatitis C / Q000628:therapy / Q000821:virology*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D007963:Leukocytes, Mononuclear / Q000821:virology*; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D011379:Prognosis; D012367:RNA, Viral / Q000032:analysis*; D012307:Risk Factors
chemical_list: D017931:DNA Primers; D016898:Interferon-alpha; D012367:RNA, Viral